Skip to main content

Table 5 Multivariate analysis for disease free survival

From: Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy

  HR 95% CI P-value
tumor size (≥ 5 cm) 1.260 (0.602, 2.637) 0.539
number of lymph nodes (≥ 10) 7.366 (2.982, 18.197) < 0.001
ER (-) 0.988 (0.316, 3.089) 0.984
PR (-) 0.717 (0.254, 2.025) 0.530
bcl-2 (-) 2.895 (1.090, 7.690) 0.033
p53 (> 25%) 1.065 (0.507, 2.237) 0.868
c-erbB2 (3+) 3.535 (1.616, 7.731) 0.002
Ki-67 (≥ 5%) 1.247 (0.614, 2.534) 0.541